Icosavax, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2017-01-01
- Employees
- 60
- Market Cap
- -
- Website
- http://www.icosavax.com
A Study of IVX-A12 in Adults Participants
Phase 2
Completed
- Conditions
- Healthy Participants
- Interventions
- Biological: Licensed RSV Vaccine
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Icosavax, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT06481579
- Locations
- 🇺🇸
Icosavax Investigational Site US011, Lenexa, Kansas, United States
🇺🇸Icosavax Investigational Site US022, Anaheim, California, United States
🇺🇸Icosavax Investigational Site US021, Rolling Hills Estates, California, United States
A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age
Phase 2
Active, not recruiting
- Conditions
- Healthy
- Interventions
- Biological: IVX-A12Biological: Placebo
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Icosavax, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT05903183
- Locations
- 🇺🇸
Velocity Clinical Research-Boise, Meridian, Idaho, United States
🇺🇸AMR Lexington, Lexington, Kentucky, United States
🇺🇸AMR Phoenix, Tempe, Arizona, United States
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: IVX-121Biological: PlaceboBiological: IVX-241Other: MF59®
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Icosavax, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05664334
- Locations
- 🇺🇸
PanAmerican Clinical Research, Brownsville, Texas, United States
🇺🇸CenExcel ACMR, Atlanta, Georgia, United States
🇺🇸CenExcel RCA, Hollywood, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath